Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

President Trump And Drug Pricing: Rhetorical Improvement But Uncertainty Remains

Executive Summary

In his first address to Congress, President Trump didn’t drop drug pricing as a theme, but he also didn’t accuse the industry of 'getting away with murder.' For innovators, that’s at least a rhetorical improvement. Now the debate becomes what the US president means by prices that are 'artificially' high.

You may also be interested in...



Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump

The disconnect between what Donald Trump says about drug pricing in unscripted settings and what the Administration says in more formal, policy-articulating contexts is very stark. For biopharma companies, the 'official' statements are reassuring – but it would be dangerous to discount Trump’s populist instincts altogether.

Trump Slams FDA Regulations In Joint Session Of Congress

US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.

Carrots and Stick: Biopharma At The White House

Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel